How much omega-3 do I need, and is algae oil as good as fish oil?

Food sources vary widely in EPA and DHA content. A 3-ounce serving of Atlantic salmon provides roughly 1,200-2,400 mg of combined EPA and DHA, while the same amount of canned tuna provides about 200-500 mg. Sardines, mackerel, herring, and anchovies are also excellent sources¹.

Fish oil supplements typically come in three molecular forms: natural triglyceride, ethyl ester, and re-esterified triglyceride. Bioavailability differs meaningfully between these forms: in a controlled trial in 72 volunteers, EPA+DHA bioavailability from re-esterified triglycerides was superior (124%) compared with natural fish oil, bioavailability from ethyl esters was inferior (73%), and free fatty acids (91%) did not differ significantly from natural triglycerides². A standard fish oil capsule (1,000 mg of oil) typically contains 300-500 mg of combined EPA and DHA, though concentrated formulations may contain 700-900 mg.

Algae oil is derived from microalgae, the original source of omega-3s in the marine food chain. Fish accumulate EPA and DHA by eating algae and smaller fish, so algae oil goes directly to the source. Most commercially available algae supplements are rich in DHA, though newer formulations also provide meaningful EPA^3,5. Studies show algae-derived DHA is bioequivalent to DHA from fish oil⁵.

Dosing guidance depends on your goals. For general health maintenance, 250-500 mg/day of combined EPA and DHA is the most commonly cited range¹. For triglyceride reduction, clinical trials have used 2,000-4,000 mg/day of EPA and DHA, typically under medical supervision⁴. The FDA considers up to 3,000 mg/day from supplements to be generally recognized as safe⁴.

Taking omega-3 supplements with a meal containing some fat is the usual advice, because concomitant food intake and the fat content of the meal influence how well omega-3 fatty acids are absorbed⁶.

The choice of omega-3 source and formulation has meaningful implications for bioavailability, sustainability, and clinical outcomes.

Bioavailability of different formulations. Dyerberg et al. (2010) compared three concentrated preparations (ethyl esters, free fatty acids, and re-esterified triglycerides) with placebo oil in a double-blinded design, and with fish body oil and cod liver oil in single-blinded arms. Seventy-two volunteers were given approximately 3.3 g of EPA plus DHA daily for 2 weeks, and increases in absolute amounts of EPA and DHA in fasting serum triglycerides, cholesterol esters and phospholipids were examined. Bioavailability of EPA+DHA from re-esterified triglycerides was superior (124%) compared with natural fish oil, whereas the bioavailability from ethyl esters was inferior (73%); free fatty acid bioavailability (91%) did not differ significantly from natural triglycerides². Schuchardt and Hahn (2013) reviewed how the chemical binding form (ethyl esters, triacylglycerides or phospholipids), matrix effects (capsule ingestion with concomitant food intake, fat content of the food) and galenic form (such as microencapsulation or emulsification) influence the bioavailability of omega-3 fatty acids, and called for systematic investigation of the bioavailability of omega-3 formulations⁶. These findings have practical implications for supplement selection and dosing instructions.

Algae-derived omega-3s. Lane et al. (2014) reviewed the evidence for microalgal omega-3 sources and found that algae oil DHA is bioequivalent to fish-derived DHA in randomized controlled trials, producing comparable increases in blood DHA levels⁵. Adarme-Vega et al. (2012) described the cultivation of DHA-producing microalgae species, primarily Schizochytrium and Crypthecodinium, noting that algal production avoids the heavy metal contamination and environmental concerns associated with fish-derived oils³. Algae cultivation also avoids bycatch and overfishing concerns, making it the more sustainable option from an ecological standpoint.

Regulatory and safety considerations. The FDA has issued qualified health claims for omega-3 fatty acids, acknowledging supportive but not conclusive evidence for cardiovascular benefit. The agency considers dietary supplements providing up to 3 g/day of EPA and DHA to be generally recognized as safe, while prescription omega-3 products delivering 4 g/day are approved specifically for severe hypertriglyceridemia (>500 mg/dL)⁴. Common side effects at higher doses include fishy aftertaste, gastrointestinal discomfort, and a theoretical increase in bleeding risk, though the latter has not been confirmed in clinical trials at doses up to 4 g/day.

Dosing evidence by indication. The NIH Office of Dietary Supplements summarizes dosing evidence as follows: general cardiovascular health, 250-500 mg/day combined EPA+DHA; secondary prevention of coronary heart disease, 1,000 mg/day; triglyceride lowering, 2,000-4,000 mg/day. There is no established Recommended Dietary Allowance (RDA) for EPA or DHA specifically, though the Adequate Intake for total omega-3s (including ALA) is 1.1-1.6 g/day for adults. The International Society for the Study of Fatty Acids and Lipids (ISSFAL) recommends a minimum of 500 mg/day combined EPA+DHA for cardiovascular health¹.

For individuals who do not consume fish, an algae-based supplement providing at least 250 mg DHA (and ideally EPA as well) is a well-supported alternative with equivalent bioavailability and no concerns about marine contaminants^3,5.